Topical applications of allogeneic adipose-derived mesenchymal stem cells ameliorate the canine keratoconjunctivitis sicca

Li-Ning Wei1,2, Ching-Ho Wu1,3, Chung-Tien Lin1,2* and I-Hsuan Liu4,5*

Abstract

**Background:** Canine keratoconjunctivitis sicca (KCS) is predominantly an immune-mediated disease. Current therapy of canine KCS is mainly by immunosuppressant, but the effectiveness was limited in some patients. In the past few years, some studies showed the results of the use of mesenchymal stem cells in treating canine KCS via periocular injections. However, the periocular injection procedure requires sedation or general anesthesia, and may lead to iatrogenic or incidental injury during the injection process. The aim of this study was to investigate the efficacy of topical allogenic canine adipose-derived mesenchymal stem cells (cAD-MSCs) in clinical patients of canine KCS.

**Results:** The cAD-MSCs used in this study were characterized for their capability of tri-lineage differentiation and immunomodulatory properties. In addition, preparation methods for eye drops of cAD-MSCs was developed and its optimal preservation was tested. The canine KCS patients were recruited for clinical trial and divided into two groups based on their history of previous treatment. All patients received topical cAD-MSCs treatment once per week for 6 consecutive weeks and complete ophthalmic examinations were performed 1 week before treatment (week 0) and at 3rd, 6th, 9th weeks, respectively. The results showed that the quantity and quality of tears have improved significantly following topical cAD-MSCs treatment based on Schirmer's tear test-1 and tear break-up time. More than half of all patients were found improved in the tear quantity. In particular, 56.5% of the patients that were unresponsive to prior immunosuppressant therapy had an effective increase in tear volume. The severity of clinical signs was also ameliorated according to the numeric rating scale score from both patient owners and the clinician.

**Conclusion:** To sum up, topical cAD-MSCs may be beneficial especially in KCS patients with poor owner compliance for frequent daily use of eye drops or those who are unresponsive to immunosuppressant therapy.

**Keywords:** Adipose-Derived Mesenchymal Stem Cells, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Ophthalmic Administration

Background

Keratoconjunctivitis sicca (KCS), or dry eye syndrome (DES), is one of the commonly recognised ocular disease in human and canine patients. KCS is characterized by the development of ocular surface damage, and is literally an inflammatory condition of the cornea and conjunctiva, which is secondary to a deficiency of the pre-corneal tear film. The tear film not only protects and lubricates the eyes, but also provides the cornea with the oxygen and nutrients [1]. Accordingly, the tear film deficiencies...
may lead to dehydration and malnutrition of the corneal and conjunctival epithelium and consequently recurrent corneal ulceration and infection. As a result, the eyes show clear to yellowish discharge with corneal scarring, neovascularization, hyperpigmentation, hyperkeratinization, and may lead to vision reduction or even loss in the end stage.

In principle, KCS is categorized to quantitative KCS and qualitative KCS by tear film deficiency. Quantitative KCS is a decrease or lacking in the aqueous component of the tear film and is more common found in veterinary medicine. Although the causes of KCS in canine patients include congenital, metabolic, infectious, drug induced, neurogenic, radiation and iatrogenic, the predominantly most common cause is the idiopathic KCS (iKCS). In the recent decades, iKCS is generally considered to have an immunological and likely an autoimmune cause [2]. Therefore, more and more studies used the term “immune-mediated” instead of “idiopathic” KCS for iKCS. It is now believed that canine KCS is predominantly a T-cell immune-mediated condition as most inflammatory cells in the lacrimal tissue of KCS-affected dogs were CD3+ T cells [3]. This T-cell mediated reaction is likely compromise the tissue integrity and functionality of lacrimal glands and in turn causes KCS. Accordingly, current primary medical therapy against KCS usually includes immunosuppressants.

The first topical immunosuppressant used in dogs was cyclosporine A (CsA), and a series of studies showed that CsA blocks normal production of interleukin-2, thereby inhibits proliferation of T-helper and cytotoxic T cells in the lacrimal gland, and consequently results in marked regression of chronic corneal neovascularization and pigmentation with rapid healing of indolent corneal ulcers [4–6]. CsA is now commercially available as 0.2% ointment (Optimmune, Merck Animal Health, USA) in veterinary medicine. However, CsA can cause hypersensitivity to the eyes in some patients and is less effective especially in more advanced canine KCS. Alternatively, topical application of aqueous suspension of tacrolimus twice daily might be used as a replacement in the patients that did not respond well to CsA [7, 8]. With similar molecular mechanism to tacrolimus, twice daily eye drops of immunosuppressant pimecrolimus also showed better therapeutic effect than CsA [9]. Unfortunately, there are still a significant number of canine KCS patients do not respond to immunosuppressant treatment. Furthermore, chronic topical immunosuppressive therapy for KCS may lead to risks for other complications such as corneal and conjunctival infections and corneal squamous cell carcinoma dogs [10, 11].

Due to its multipotential differentiation capability, mesenchymal stem cells (MSCs) have attracted attention for regenerative medicine in the past two decades. According to the International Society for Cellular Therapy, the minimal criteria for cells to be recognized as MSCs include: (1) adherence to plastic in standard culture conditions; (2) specific surface antigen expression. More precisely, 95% above of MSCs must express CD73, CD90 and CD105 and 2% below of MSCs must lack expression of CD34, CD45, CD11b or CD14, CD79α or CD19 and HLA-DR, that is an MHC class II cell surface receptor; and (3) multipotent differentiation potential. Under standard conditions, the MSCs must be able to differentiate to osteoblasts, adipocytes and chondroblasts in vitro [12]. Interestingly, instead of the differentiation potentials of mesenchymal stem cells in cell replacement, current research on MSCs is focused on its immunological properties, paracrine effect, and MSC homing in cell empowerment [13].

Recent studies indicated that MSCs exert immunomodulatory effects via multiple mechanisms including indoleamine-pyrole 2,3-dioxygenase (IDO) via adenosine signaling, prostaglandin E2 (PGE2) via cyclooxygenase pathway, transforming Growth Factor Beta (TGF-β) singaling pathway and nitric oxide (NO) via NO synthases, and thereby inhibit the proliferation and activation of T cell and antigen presenting cells [14–17]. Since MSCs can be obtained from many sources in the body, a study compared canine bone marrow-derived stem cells (cBM-MSCs) and adipose-derived stem cells (cAD-MSCs) for their immunomodulatory efficacy. Interestingly, the two populations of MSCs showed comparable potential to suppress T cells, although TGF-β and adenosine signaling pathways seemed more important for cAD-MSCs while cyclooxygenase, TGF-β and adenosine signaling pathways all contribute to T-cell suppressive effect of cBM-MSCs [18].

Considering that immune-mediated KCS constitute a predominant part of clinical cases, the use of MSCs for KCS treatment has the potential to be an alternative therapeutic option. Accordingly, three independent groups performed intra-ocular, intra-lacrimal or intra-venous injection of allogeneic cAD-MSCs in KCS patients and showed significantly improvements in the tear production and other clinical signs [19–21]. Because repeated periorcular transplantations of allogeneic MSCs in dogs were determined to be safe in vivo with systemic immunomodulatory effects [22], it is likely that topical application of cAD-MSCs could also exert similar therapeutic effect in KCS. In line with this speculation, topical application of MSCs successfully improved the tear production and tear film stability in an induced dry eye syndrome in rat model [23].

The aim of this study is to evaluate the therapeutic effect of topical application of cAD-MSCs in treating clinical canine KCS patients.
Results
Isolation and characterization of cAD-MSCs for iKCS treatment

Five clinically healthy female canine donors aged between 1.5 to 6 years old, weighted from 2 to 23 kg receiving ovariohysterectomy (OHE) were included for cAD-MSC donation. The cAD-MSCs were isolated and harvested successfully from omental adipose tissue from each donor. The isolated cells showed fibroblast-like morphology with the ability to adhere to plastic surface (Fig. 1A). Cells isolated from omental fat contained CFU and the number of CFU was $15.3 \pm 2.3$ ($n = 6$) at seeding density of 500 cells/cm$^2$ and $12.0 \pm 3.6$ ($n = 6$) at seeding density of 300 cells/cm$^2$, respectively. These cells formed white nodule-like colonies under osteogenic conditions for 7 days, and these white nodule-like colonies were strongly stained by ARS indicating successful osteogenic differentiation (Fig. 1B). Furthermore, the cells stopped expanding and began to fill with small vacuoles after 15 days in adipogenic induction medium. These small vacuoles were droplets of neutral lipids as stained by 0.5% ORO (Fig. 1C). In addition, the cells conformed into a spherical micromass on the second day in the chondrogenic induction medium. After 30 days cultured in chondrogenic induction medium, the micromass was sectioned and showed the typical glycosaminoglycans accumulation (pink-purple hue in the center) with 0.1% of toluidine blue O staining (Fig. 1D). The isolated cells were moderately expressed CD44 and predominantly negative for CD34 and CD45, while positive for CD90 at both passage 3 (Fig. 1E-H) and passage 7 (data not shown). Taken together, the cells isolated from omental adipose tissue during canine OHE were cAD-MSCs.

As iKCS are generally considered immune-mediated, it is key to test whether cAD-MSCs were immune-modulatory. The cAD-MSCs at passage 5 were subjected to mitogen-induced proliferation assay of PBMC. The PBMC proliferation index showed significantly decreased in all cAD-MSC treated groups and in a dose dependent fashion (Fig. 2). This result indicates that cAD-MSCs using in this study exert immunomodulatory activity and inhibit mitogenic responses of PBMCs.

To evaluate the feasibility of the topical and non-invasive method to treat canine iKCS patients with cAD-MSCs, we first evaluated the cell viability of cAD-MSC after prepared as eye drops. The eye drops stored at 4°C in the dark showed 95% viability after 2 hours and remained 82% viability after 6 hours. On the other hand, the cell viability in cAD-MSCs eye drops stored at room temperature in the dark dropped to 92% at first hour and 81% after 4 h. By 5 h, the cell viability of cAD-MSCs in room temperature group dropped to 79%. Accordingly, all the clinical study results in this report used cAD-MSCs eye drops that were stored at 4°C in the dark and topically applied to patients within 2 hours after preparation.

Study population in the clinical trial
In total of 23 client-owned patient dogs were included in this study and received topical cAD-MSCs treatment with complete follow-up examinations. Based on previous treatment history, these patients were divided...
into two groups for analysis. Naïve group included 23 eyes of 12 dogs without history of immunosuppressant therapy (n = 23). Noticeably, one of patient was unilateral KCS. Refractory group included 21 eyes of 11 dogs that were unresponsive to previous immunosuppressant therapy (n = 21). One of the eyes was excluded because the eye was already enucleated due to refractory glaucoma secondary to lens luxation. Therefore, the total number of eyes evaluated in this study was 44. The age ranged from 5 to 15 years old in naïve group with a mean age at 7.91 ± 3.33 years old. The age ranged from 1 to 14 years old in refractory group with a mean age at 8.83 ± 3.79 years. Eleven dogs were spayed females, two were sexually intact females, nine were castrated males, and one was sexually intact males. Most subjects were purebred representing nine breeds and only one crossbred. The Maltese (n = 5) were the largest group of patients enrolled, followed by Dachshund (n = 4), Yorkshire terrier (n = 4), Poodle (n = 3) and Charles Spaniel (n = 1), Beagle (n = 1), Miniature Schnauzer (n = 1), Pug (n = 1), and Chihuahua (n = 1). The 11 patients in refractory group remained unresponsive to sustained immunosuppressant therapy at a mean period of 2 years and 4 months (ranged from 4 months to 5 years). Optimmune (n = 1), 1 to 2% CsA compounded in corn oil (n = 6) or 0.03% tacrolimus (n = 5) were administered in these patients as prior immunosuppressant. Information of each patient was presented in Tables 1 and 2.

The efficacy of topical cAD-MSCs

To test the efficacy of topical application of cAD-MSC eye drops for iKCS, ophthalmic examination results were statistically analyzed. All patients received topical treatment consisted of 2 × 10^6 cAD-MSCs weekly for 6 consecutive weeks and complete ophthalmic examinations at baseline, 3rd, 6th and 9th week.

The mean STT-1 values of each eye at baseline in the naïve group and refractory group were 5.62 ± 0.22 mm/min and 4.91 ± 0.25 mm/min. The mean STT-1 value showed a significant increase at the third week (P < 0.01) and a further significant increase at ninth week (P < 0.05 compared to sixth week) (Fig. 3A). Interestingly, the mean STT-1 values increased in refractory group also showed a similar significant increase at the third week (P = 0.01) but the trend of improvement stalled thereafter.

Table 1 Information of each patient in naïve group

| Age | Gender | Breed              | STT OD | STT OS | TBUT OD | TBUT OS |
|-----|--------|--------------------|--------|--------|---------|---------|
| 13  | NM     | Beagle             | 0      | 0      | 0       | 0       |
| 15  | NM     | Miniature schnauzer| 0      | 0      | 0       | 0       |
| 6   | NF     | Miniature dachshund| 3      | 9      | 6       | 10      |
| 6   | NF     | Miniature dachshund| 12     | –      | 3       | –       |
| 7   | IF     | Miniature poodle   | 6      | 6      | 3       | 3       |
| 7   | NF     | Miniature poodle   | 14     | 7      | 1       | 3       |
| 10  | NM     | Maltese            | 3      | 11     | 3       | 5       |
| 7   | NF     | Maltese            | 0      | 3      | 2       | 2       |
| 5   | NF     | Maltese            | 6      | 0      | 2       | 2       |
| 5   | NM     | Yorkshire terrier  | 12     | 9      | 3       | 2       |
| 6   | IM     | Yorkshire terrier  | 9      | 8      | 5       | 6       |

NM neutered male, NF neutered female, IM intact male, IF intact female, OD oculus dextrus, OS oculus sinister

Fig. 2 Immunosuppressive properties of cAD-MSCs. The PBMC showed significantly decreased proliferation index with the presence of cAD-MSC in a dose dependent manner. All data points were presented in clear circle and the mean with standard deviation was plotted for each group. Each letter indicated a distinct statistical groups.
(Fig. 3B). However, two-way ANOVA failed to detect significant variation between two groups ($P = 0.612$).

In this study, STT-1 values of each eye increased by more than 5 mm/min were defined as well responder. Accordingly, at the third week, 6 out of 21 eyes in naïve group and 7 out of 23 eyes in refractory group were well responder to cAD-MSCs. Nearly half of patients (10/21 and 11/23) in both groups showed well responses at sixth week. At the ninth week, the percentages of well-responders reached 57.1% (12/21) in naïve group and 56.5% (13/23) in refractory group (Table 3). However, similar to the STT-1 values, no statistically significant

| Age | Gender | Breed            | STT OD | STT OS | TBUT OD | TBUT OS | Previous treatment / period          |
|-----|--------|------------------|--------|--------|---------|---------|-------------------------------------|
| 1   | IF     | Yorkshire terrier| 10     | 0      | 3       | 3       | 2% CsA / 1Y                         |
| 6   | NM     | mixed            | 17     | 21     | 11      | 9       | 2% CsA / 5Y                         |
| 14  | NM     | Miniature dachshund| 8     | 3      | 3       | 3       | 1% CsA / 3Y                         |
| 5   | NF     | Pug              | 0      | 11     | 0       | 3       | 1% CsA / 1Y                         |
| 14  | NM     | Yorkshire terrier| 0      | 0      | 0       | 3       | 2% CsA / 2Y; TA / 1Y                |
| 8   | NF     | Maltese          | 0      | 3      | 3       | 5       | TA / 1Y                             |
| 9   | NF     | Maltese          | 0      | 4      | 2       | 2       | TA / 3Y                             |
| 10  | NF     | Maltese          | 15     | 5      | 3       | 3       | 1% CsA / 2Y                         |
| 8   | NM     | King Charles Spaniel| 0    | 0      | 3       | 0       | Optimmune / 1Y                      |
| 13  | NM     | Chihuahua        | 0      | 18     | 0       | 3       | 1% CsA / 2Y; TA / 3Y               |
| 9   | NF     | Miniature dachshund| 0    | 0      | 3       | 2       | 1% CsA / 3Y                         |
| 9   | NF     | Miniature poodle | 10     | 5      | 1       | 2       | TA / 4Y                             |

**Table 2** Information of each patient in refractory group

*NM neutered male, NF neutered female, IM intact male, IF intact female, OD oculus dextrus, OS oculus sinister, CsA Cyclosporine A, TA Tacrolimus, Y years, M months

**Fig. 3** Effect of cAD-MSCs eye drops on clinical signs of KCS. A **B** STT-1 were statistically increased in both naïve (A) and refractory (B) groups indicating the improvement in tear quantity. C **D** TBUT were statistically increased in both naïve (C) and refractory (D) groups indicating the improvement in tear quality. The data were presented as mean with standard deviation, and each letter indicated a distinct statistical groups
differences in response rates were detected between the two groups.

Mean tear break-up time (TBUT) of each eye at baseline was 2.476 ± 0.087 seconds in naïve group patients, and significantly increased to 6 ± 0.12 seconds at sixth weeks, albeit the trend of improvement stalled thereafter (Fig. 3C). In the refractory group, the mean TBUT at baseline was 2.52 ± 0.086 seconds. Interestingly, this value significantly increased to 4.35 ± 0.10 seconds at the third week and showed a further significant increase to 7.57 ± 0.13 at ninth week (Fig. 3D). Similarly, two-way ANOVA failed to detect significant variation between two groups in TBUT (P = 0.663).

Clinical signs of all included patients were evaluated by the same clinician of the Ophthalmology Department and also observed by the owners. The numeric rating scale (NRS) score ranged from 1 to 5 was used to assess severity of KCS signs. At baseline, the mean scores for signs of mucoid discharge, conjunctival hyperemia, and corneal change in all patients by the clinician and owners were 3.52 ± 0.045 (Fig. 4A) and 4.41 ± 0.027 (Fig. 4B), respectively. By the sixth week, the NRS score significantly decreased to 2.04 ± 0.043 (Fig. 4A) and 2.93 ± 0.027 (Fig. 4B) according to both clinician evaluation and owner observation. Interestingly, an one-year follow-up of clinical signs was obtained from each patient owner. The mean total scores for signs of mucoid discharge, conjunctival hyperemia, and corneal change in all patients observed by owners 1 year after the last cAD-MSC treatment was 2.71 ± 0.026. This score remained to be significantly lower than the baseline (P < 0.0001) and comparable to the score at ninth week (P > 0.9999) (Fig. 4B).

Discussion

In this study, we demonstrated that non-invasive topical application of cAD-MSCs ameliorates canine iKCS. Although cAD-MSCs may exert comparable immunomodulatory effect as cBM-MSCs via slightly different mechanisms [18], there are several advantages to choose adipose tissue as the source of MSCs. One of the predominant reason to fail in obtaining cBM-MSC is bone marrow failure. Previous study showed that 30-40% of bone marrow aspiration from humerus and femur failed to harvest cBM-MSCs and most likely due to bone marrow failure in these bones [24]. On the contrary, cAD-MSCs were successfully harvested and isolated in all five omental adipose tissues collected in this study. Furthermore, the omental adipose tissues were collected during OHE procedures, which were unrelated to this study, and hence minimize the distress caused to the animal for the isolation of MSCs. In accordance with previous study that cAD-MSCs can be obtained from small amount of adipose tissue [25], 5 mL of adipose tissue yielded about 3 × 10⁷ cells in primary culture on average in this study. We further expand cAD-MSCs with a dilution factor of 1:2 to 1:3 in every passage. As we used of 2 × 10⁶ cells at passage 4 to 6 in every treatment, one harvest could easily provide enough cAD-MSCs for more than 120 treatments.

Although MSCs originally attracted attentions due to its multiple differentiation potentials, it is now generally acknowledged that transplanted MSCs do not persist in the host. Allogenic MSC-derived ectopic

Table 3

| Group     | N  | 3rd week | 6th week | 9th week |
|-----------|----|----------|----------|----------|
| Naïve     | 21 | 28.6%    | 47.6%    | 57.1%    |
| Refractory| 23 | 30.4%    | 47.8%    | 56.5%    |

Patients with STT-1 values increased more than 5 mm/min compared to pre-trial STT-1 values were defined as responders

![Fig. 4](image_url)

**Fig. 4** Effect of cAD-MSCs eye drops on clinical assessment. **A** The veterinarian assessment of clinical signs using NRS showed a statistically significant decrease after 6 weeks of administration of cAD-MSCs. **B** Owners assessment of clinical signs using NRS also showed a statistically significant decrease after 6 weeks of CAD-MSC treatment. The data represent the mean of hyperemia, discharge, corneal change and each letter indicated a distinct statistical groups.
tissue engraftment hardly occur [26]. The “hit-and-run” model suggests that the various beneficial effects of MSC transplantation might be predominantly attributed to the paracrine effects, by which the MSCs interact with and alter the activities of host cells including the immune milieu [27]. In this study, the immunomodulatory activity of cAD-MSC was also demonstrated by mitogen-induced proliferation assay of PBMCs, and a dose-dependent response between MSC:PBMC ratios of 1:256 to 1:8 was observed (Fig. 2). Although fitted into different response models, similar results were also observed previously with a similar dose-dependent range in MSC:PBMC ratios [28, 29]. Interestingly, it is consistently found that the immunomodulatory effect of MSCs saturated when the MSC:PBMC ratio above 1:10. A healthy dog have about 4 × 10^7 cells/mL [31].

In our study, both refractory and naïve KCS patients responded to the treatment of cAD-MSCs in similar ways. This result implied that cAD-MSCs ameliorate the canine iKCS via distinct mechanisms from immunosuppressant eye drops. The immune suppressive pathways in canine MSCs have not been thoroughly studied, but a recent study showed that topical application of MSCsameliorates inflammatory levels in KCS patient dogs indicated by reduced CD4, IL1, IL6 and TNFα levels [36]. It is generally agreed that canine iKCS is an autoimmune condition predominantly mediated by T-cell population [3]. Immune suppressant eye drops such as CsA, tacrolimus and pimecrolimus modulate T-cell response by blocking signaling pathways of T-cell receptor via calcineurine [37]. It is likely that MSCs involve in the modulation of T-cell response via multiple secretory pathways. For example, evidence showed that TGF-β signaling
pathways and adenosine signaling are both involved in the suppression of T-cell activation by AD-MSCs [18]. Although cell-free therapeutic reagents are more appealing than MSCs. Application of simple MSC secreted materials might not work as effective as MSCs, since the immune modulatory activity of MSCs are dependent on the stimulatory immune milieu [38]. It is of interest to further investigate the varieties of immunomodulatory mechanisms of MSCs and the etiology of iKCS for the development of cell-free reagents. In addition, according to the result of this study, the combined administration of cAD-MSC and immunosuppressant eye drops might result in an even greater improvement.

Conclusion
In conclusion, weekly administration of cAD-MSCs for 6 consecutive weeks increased the quantity and quality of tears and improved clinical signs in clinical canine KCS patients. Most patients appeared relieved from those irritation and uncomfortable signs, and thus their quality of life seemed improved following treatment. Our findings confirm the interest to develop cAD-MSCs as a potential therapy for canine KCS, especially for those unresponsive to immunosuppressant therapy.

Methods
Isolation of canine adipose-derived mesenchymal stem cells
All experimental procedures in this study were reviewed and approved by National Taiwan University Veterinary Hospital (Clinical Research No: 000030 and 000031) and the Institutional Animal Care and Use Committee of National Taiwan University (IACUC No: NTU106-EL-00097).

To obtain cAD-MSCs, fat donors were recruited from canine patients in National Taiwan University Veterinary Hospital (NTUVH) with the owners fully consented. The inclusion criteria of donors were modified from the canine blood donors as following [24, 39]: (1) between one to eight years old; (2) weight more than 5 kg and body condition scoring (BCS) 3/5 or above; (3) be up-to-date on vaccinations; (4) have no prior history of blood-borne illness; (5) be fit, healthy and not on medication. In addition, the recruited patients were already scheduled for laparotomy unrelated to this study and the adipose tissues were then harvested from omental adipose tissue after the BMI and BCS were assessed. A total of 51 adipocytes were isolated for the study. Of these, 23 donors were used for the immunosuppressant therapy and 18 for the cAD-MSCs treatment.

For chondrogenic differentiation, each set of 2.5 × 10^5 cells was centrifuged at 300 × g for 5 minutes, and the cells were cultures in chondrogenic induction medium (DMEM supplemented with 1% FBS, 10 ng/mL transforming growth factor beta 1 (TGF-β1; R&D Systems, Minneapolis, MN, USA) in pure medium). The viable cells were estimated using a hemocytometer with 0.2% trypan blue staining (Gibco). The cells were seeded at a density of 1 × 10^4 cells per cm^2 with the culture medium replaced every 3 days until 70-80% confluence.

Tri-lineage differentiation of cAD-MSCs
To confirm the multipotent differentiation potentials, the cells were incubated at two different seeding densities (350 and 500 cells/cm^2) in culture medium for 10 days [42]. The cells were washed with PBS, fixed by methanol (Sigma-Aldrich) for 5 minutes, and then stained with KaryoMAX Giemsa (Gibco) for 20-30 minutes. The cells were rinsed in deionized water and colonies with a 2-mm or larger diameter were counted as a colony-forming unit (CFU).
Minneapolis, MN, USA), 6.25 μg/mL of insulin (Sigma-Aldrich) and 50 nM of L-ascorbic acid for up to 30 days with the chondrogenic induction medium changed every 3 days. To assess the chondrogenic differentiation, the spherical micromasses were fixed in 10% formaldehyde for 1 hour and prepared into paraffin sections in 6-μm thickness. After dewaxing and rehydration, the slides were stained with 0.1% of toluidine blue O (Sigma-Aldrich) for 5 minutes, washed with PBS, mounted in mounting medium (Leica Biosystems, Wetzlar, DE) and documented for the sulfated glycosaminoglycans (GAG) accumulation under a microscope (DM2500, Leica Microsystems, Wetzlar, DE).

For adipogenic differentiation, the cells were plated at the seeding density of 10,000 cells/cm² to for amplification until confluence and then were transferred to adipogenic induction medium (culture medium supplemented with 1 μM dexamethasone, 10 μg/mL insulin, 100 μM indomethacin and 0.5 μM isobutyl-methylxanthine) for 35-40 days with the adipogenic induction medium changed once every 3 days. The cells were fixed in 10% formaldehyde for 10 minutes, dehydrated with 1 mL of propylene glycol (JT Baker, Phillipsburg, NJ, USA) for 1 minute, and then immersed in 200 μL of 0.5% Oil Red O (ORO) (Sigma-Aldrich) for 15 minutes to visualize the lipid droplets. After the staining was stopped with 1 mL of 60% propylene glycol, the cells were washed with deionized water and assessed under a microscope.

**Immunophenotyping of cAD-MSCs**

To evaluate the immunophenotypes of isolated cAD-MSCs [24], the cells were mixing with antibody and stored at 4 °C in the dark for at least 30 minutes. After washing with PBS with 2% FBS, the cells were fixed in PBS with 1% FBS and 3% formaldehyde, the cells were then analyzed for the expressions of surface markers by flow cytometry (FC500, Beckman-Coulter, Fullerton, CA). The fluorescence-conjugated or isotype control antibodies used in this study were as listed (Table 4).

**Immunomodulatory effect of cAD-MSCs**

To estimate the immunomodulatory activities of cAD-MSCs, the mitogen-induced proliferation assay of peripheral blood mononuclear cells (PBMCs) was adopted from previously published methods [44, 45]. Briefly, canine whole blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes (BD, Franklin Lake, NJ, USA) and centrifuged at 1200 RPM for 10 minutes. The cells were re-suspended with pre-warmed RPMI-1640 medium (Gibco) containing 20% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 50 μM 2-mercaptoethanol (Sigma-Aldrich) and 55 μM Ficoll-Paque (GE Healthcare, Chicago, IL, USA). The mononuclear cells were separated by cell density gradient centrifugation. The centrifugation was started at 500 RPM and increased 100 RPM every 30 seconds till 1700 RPM for 20 minutes. After washed with RPMI-1640 medium, 1 × 10⁶ of the resulting peripheral blood mononuclear cells (PBMCs) were seeded in triplicate with the addition of a 2-fold serial dilution of the mitomycin C (10 μg/mL; Sigma-Aldrich) treated cAD-MSCs (in the dark at 37 °C for 2 hours) in 96-well plates (TPP, Trasadingen, Switzerland) followed by mitogenic stimulation using 5 μg/mL concanavalin-A (ConA; Sigma-Aldrich). The cAD-MSC only samples as well as PBMCs with or without ConA stimulation were also prepared to calculate the proliferation indexes. After 4 days in culture, the total viable cell number was analyzed by using Cell Counting Assay Kit-8 (CCK-8; Dojindo Molecular Technologies, Rockville, MD, USA) according to the manufacturer’s protocol. The absorbance at 450 nm was read by an ELISA plate reader (ThermoMax, Molecular Devices, San Jose, CA, USA). The proliferation indexes of PBMC with conA relative to without conA was considered 100% and all sample were normalized in the same fashion after the signal from cAD-MSC only control were subtracted.

**Preparation of cAD-MSCs eye drops**

To prepare cAD-MSCs into eye drops for dogs [23, 46], the cAD-MSCs at passage 4 to 6 were revived 2 hours

| Antibody     | Clone       | Vendor                      | Dose (/test) | Isotype   |
|--------------|-------------|-----------------------------|--------------|-----------|
| CD44-FITC    | YKIX337.8   | eBioscience, San Diego, CA, USA | 0.025μg      | IgG2a     |
| CD90-PE      | YKIX337.217 |                             | 0.1 μg       | IgG2b     |
| CD34-PE      | 1H6         |                             | 0.05 μg      | IgG1      |
| CD45R-PE     | YKIX753.222 |                             | 0.0015 μg    | IgG2b     |
| IgG2a-FITC (Rat) | eB2R2a |                             | 0.1 μg       |           |
| IgG1-PE (Mouse) | P3.6.2.8.1 |                             | 0.025 μg     |           |
| IgG2b-PE (Rat) | eB149/10HS |                             | 0.1 μg       |           |
before topical application, re-suspended at the concentration of $2 \times 10^6$ cells/50μL PBS solution, and then aseptically filled into sterilized 1-mL disposable syringes (Terumo, Tokyo, JP). To assess the qualities of the cAD-MSCs in the eye drops under various storage conditions, 10μL of eye drops were gently mixed with equal volume of 0.4% trypan blue and the percentages of viable cells were counted on a hemocytometer. For topical application, the AD-MSCs from different donors were not pooled but were also not segregated for each recipient.

Inclusion and exclusion criteria of patients for the clinical trial
All subjects in this study were clinical canine patients of NTUVH admitted between March 2018 to September 2018 regardless of gender, breed or age. All patients received a complete ophthalmalic examination to confirm the diagnosis of KCS by the same veterinarian (LNW) of the Ophthalmology Department. All patient-owners were fully informed the pathogenesis, clinical signs and traditional treatments of KCS as well as the safety and the course of topical cAD-MSCs treatment before entering this study. Diagnosis of KCS in the canine patients were based on the medical history, clinical signs and standard measurements of tear production using the Schirmer tear test-1 (STT-1) ($\leq 15$ mm/min) [47]. The subjects with other ocular diseases that could affect the result of this study such as corneal ulceration, or with other known causes for KCS were excluded from this study (Table 5).

Table 5 Exclusion of patients with other known causes for KCS

| Causes of KCS        | Considerations in the diagnostic process                                      |
|----------------------|-------------------------------------------------------------------------------|
| Congenital           | onset of clinical signs less than 6-month-old                                 |
|                      | STT $\leq 5$ mm/min                                                          |
|                      | absence of other known causes of KCS                                        |
|                      | lack of response to topical immunosuppressant                               |
| Metabolic            | Blood exam/clinical signs                                                    |
| Infectious           | History/PCT/blood exam/biopsy                                                |
| Drug induced         | History                                                                       |
| Neurogenic           | Physical exam (ipsilateral dry nose)/Neurological exam                      |
|                      | (facial paralysis, Horner’s syndrome)                                        |
| Iatrogenic           | History                                                                       |

In addition, subjects topically or systemically treated by any of the following drugs within 14 days before the study were also excluded from this study: corticosteroids, atropine, pilocarpine, sulfa-containing drugs and immunosuppressants such as CsA, pimecrolimus, or tacrolimus. As the majority of the subjects used artificial tear routinely before joining this study, the subjects kept using the same type and frequency of artificial tear after they joined this study to ensure that AD-MSC treatment was the only variation factor of the KCS patients between before and after joining the clinical trial.

This is a prospective study aiming to evaluate the therapeutic effect of topical cAD-MSCs application in canine KCS. In considering the welfare of the clinical patients, negative control group was omitted in this study as canine KCS progresses robustly without treatment [4, 7]. The therapeutic effect was estimated by comparing the treated results to the baseline conditions. As AD-MSCs can inhibit T-cell activation and proliferation [14–17], it is intriguing whether cAD-MSCs trigger the same therapeutic pathway as commonly used immunosuppressants and therefore might show less significant therapeutic effect to refractory KCS patients. To further investigate the effect of AD-MSCs on refractory KCS patients, the subjects were segregated into two groups: naïve group included subjects without any previous immunosuppressant treatment, and refractory group included subjects unresponsive to prior immunosuppressant treatment. In accordance with the exclusion criteria, all subjects in refractory group had stopped immunosuppressant treatments for at least 14 days.

Trial protocol and ophthalmic examinations
All subjects received a drop of 50μL PBS containing $2 \times 10^6$ cAD-MSCs during weekly outpatient appointment for 6 consecutive weeks (Fig. 5). A complete set of ophthalmic examinations was performed before (baseline), during (third and sixth week) and after treatment (ninth week) respectively (Fig. 5). To quantify the clinical signs of the patients, a five-point NRS was designed to describe the severity of mucoid discharge, conjunctival hyperemia, and corneal changes by both subject owners and the veterinarian. For veterinarian, the NRS was determined by using a slit-lamp biomicroscopy. The standard for NRS scores ranged from 1 to 5 were as listed (Table 6) [48]. All subject owners were also required to submit a NRS scoring result at ninth week before the disclosure of prior ophthalmic examination results. The NRS from subject owners were queried again from medical records or by telephone at least 1 year after the end of the topical cAD-MSCs therapy.

A complete set of ophthalmic examinations consists of three tests. (1) Schirmer tear test-1 (STT-1) was performed with Color Bar Schirmer tear strip (Eagle Vision, Memphis, TN, USA) to assess the aqueous tear production [49]. STT-1 value equal or less than 15 mm/min was considered abnormal. (2) Tear break-up time (TBUT) was performed using fluorescein paper (Haag-Streit AG, Köniz, Switzerland) and a slit-lamp biomicroscopy (SL-17, KOWA, Tokyo, Japan) to assess the stability of tear film. TBUT less than 15 seconds was considered abnormal.
A NRS scoring system was also implemented in this study to quantify the severity of clinical symptoms.

**Statistical analysis**

The proliferation indexes resulted from the mitogen-induced proliferation assay of PBMCs were evaluated by one-way ANOVA with Bonferroni test. The intragroup comparisons of STT-1 and TBUT were analyzed by repeated-measures analysis of variance (ANOVA) and followed by Bonferroni test. The comparisons of STT-1 and TBUT between groups were carried out by using two-way ANOVA, and the response rates between two groups were evaluated by Mann-Whitney test. The assessment of clinical signs using NRS by owners and veterinarian was analyzed using Friedman test, a non-parametric one-way ANOVA for repeated measurements, and followed by Dunn’s test for multiple comparisons. A *P*-value less than 0.05 was considered statistically significant. All data were presented as mean ± standard deviation (SD).

**Acknowledgements**

The authors would like thank Mr. Dee-Shiuh Yang and Dr. Yen-Hua Lee for the technical assistance on the isolation and handling of mesenchymal stem cells.

**Authors’ contributions**

LNW performed the study and drafted the manuscript. CHW assisted in collecting the cases and supervised the study. CTL contributed to the study conception, supervised the study and drafted as well as revised the manuscript. IHL contributed to the study conception, supervised the study, analyzed the data and drafted as well as revised the manuscript. All authors read and approved the manuscript.

---

**Table 6** The numeric rating scale (NRS) of clinical signs

| Mucoid discharge | 5 = severe | Mucopurulent crust, stinky |
|------------------|-----------|---------------------------|
|                  | 4 = advanced | Yellowish, mucoid discharge, smelly |
|                  | 3 = moderate | Yellowish, sticky discharge |
|                  | 2 = lightly | Clear, but discharge volume increased |
|                  | 1 = normal | Absent discharge |

| Conjunctival hyperemia | 5 = severe | Diffuse beefy red |
|------------------------|-----------|------------------|
|                        | 4 = advanced | Individual vessels not easily discernible |
|                        | 3 = moderate | More diffuse, deeper crimson red |
|                        | 2 = lightly | Vessels definitely injected above normal |
|                        | 1 = normal | Vessels normal |

| Corneal change | 5 = severe | Opaque, iris invisible with pigmentation, keratitis |
|               | 4 = advanced | Opalescent areas, no details of iris visible |
|               | 3 = moderate | Easily discernible translucent area, details of iris slightly obscured |
|               | 2 = lightly | Scattered or diffuse areas, details of iris clearly visible |
|               | 1 = normal | No opacity |

The NRS score was a five-point scale used to assess the severity of mucoid discharge, conjunctival hyperemia, and corneal changes by dog owners and the veterinarian.
Funding
This project was partially funded by Ministry of Science and Technology of Taiwan (105-2628-B-002-005-MY4, 109-2313-B-002-008-), Council of Agriculture of Taiwan (110-DA5-10.1-AD-U1 [12]) and National Taiwan University (110-L7236).

Availability of data and materials
All data and necessary information are included in this report.

Declarations

Ethics approval and consent to participate
All experimental procedures in this study were reviewed and approved by National Taiwan University Veterinary Hospital (Clinical Research No: 000030 and 000031) and the Institutional Animal Care and Use Committee of National Taiwan University (IACUC No: NTU106-EL-00097). All methods were performed in accordance with the relevant guidelines and regulations. All donor and patient owners were fully consented about this study and informed consent was obtained from dog owners. This study is reported in accordance with ARRIVE guidelines.

Consent for publication
Not applicable.

Competing interests
A patent application has been filed by the authors Drs. CT Lin and IH Liu relating to the content of the manuscript. The other authors (LNW, CHW) declare that they have no competing interests.

Author details
1 Institute of Veterinary Clinical Sciences, School of Veterinary Medicine, National Taiwan University, Taipei 106, Taiwan. 2 Department of Ophthalmology, National Taiwan University Veterinary Hospital, Taipei 106, Taiwan. 3 Department of Small Animal Surgery, National Taiwan University Veterinary Hospital, Taipei 106, Taiwan. 4 Department of Animal Science and Technology, National Taiwan University, Taipei 106, Taiwan. 5 Research Center for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei 106, Taiwan.

Received: 25 December 2021 Accepted: 18 May 2022 Published online: 10 June 2022

References
1. Braun RJ, King-Smith PE, Begley CG, Li L, Gewecke NR. Dynamics and function of the tear film in relation to the blink cycle. Prog Retin Eye Res. 2015;45:132–64.
2. Williams DL. Immunopathogenesis of keratoconjunctivitis sicca in the dog. Vet Clin North Am Small Anim Pract. 2008;38:251–268, vi.
3. Williams DL, Tighe AA. Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. Open Vet J. 2018;8:47–52.
4. Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol. 1989;107:1210–6.
5. Palmer SL, Bowen PA 2nd, Green K. Tear flow in cyclosporine recipients. Ophthalmology. 1995;102:118–21.
6. Moore CP, McHugh JB, Thorne JG, Phillips TE. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Invest Ophthalmol Vis Sci. 2001;42:663–9.
7. Berdoulay A, English RV, Nadelstein B. Effect of topical 0.02% tacrolimus on ocular tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol. 2005;8:225–32.
8. Radziejewski K, Balicki I. Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. Acta Vet Hung. 2016;64:313–29.
9. Ofri R, Lambrou GN, Allgower I, Graenitz U, Pena TM, Spiess BM, et al. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine. A. J. 2009;179:70–7.
10. Swinger RL, Schmidt KA Jr, Dubielzig RR. Keratoconjunctivitis associated with toxoplasma gondii in a dog. Vet Ophthalmol. 2009;12:56–60.
11. Dreyfus J, Schobert CS, Dubielzig RR. Superficial corneal squamous cell carcinoma occurring in dogs with chronic keratitis. Vet Ophthalmol. 2011;14:161–8.
12. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marin F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cell populations. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
13. Mendicino M, Bailey AM, Wonacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014;14:141–5.
14. Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21:216–25.
15. Yanez R, Oviedo A, Aldea M, Bueener JA, Lamana ML. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow-derived mesenchymal stromal cells. Exp Cell Res. 2010;316:1309–15.
16. Sato K, Ozaki K, Oh I, Meguno A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2007;109:228–34.
17. Xu C, Yu P, Han X, Du L, Gan J, Wang Y, et al. TGF-β promotes immune responses in the presence of mesenchymal stem cells. J Immunol. 2014;192:103–9.
18. Chow L, Johnson V, Coy J, Regan D, Dow S. Mechanisms of immune suppression utilized by canine adipose and bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2017;26:374–89.
19. Villatoro AJ, Fernandez V, Claro S, Rico-Llanos GA, Becerra J, Andrades JA. Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model. Biomed Res Int. 2015;2015:527926.
20. Bittencourt MK, Barros MA, Martins JF, Vasconcellos JP, Moreira BP, Pompeia C, et al. Allogeneic mesenchymal stem cell transplantation in dogs with Keratoconjunctivitis sicca. Cell Med. 2016;8:63–77.
21. Hermida-Prieto M, Garcia-Castro J, Marinas-Pardo L. Systemic Treatment of Immune-Mediated Keratoconjunctivitis Sicca with Allogeneic Stem Cells Improves the Schirmer Tear Test Score in a Canine Spontaneous Model of Disease. J Clin Med. 2021;10:5981.
22. Park SA, Reilly CM, Wood JA, Chueng DJ, Carrade DD, Deremer SL, et al. Safety and immunomodulatory effects of allogeneic canine adipose-derived mesenchymal stromal cells transplanted into the region of the lacrimal gland, the gland of the third eyelid and the knee joint. Cytotherapy. 2013;15:1498–510.
23. Beyazilydzil E, Pinarli FA, Beyazilydzil Q, Hekimoglu ER, Acar U, Demir MN, et al. Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model. Stem Cells Int. 2014;2014:250230.
24. Chang YP, Hong HP, Lee YH, Liu IH. The canine epiphyseal-derived mesenchymal stem cells are comparable to bone marrow-derived mesenchymal stem cells. J Vet Med Sci. 2015;77:273–80.
25. Neupane M, Chang C-C, Kuipel M, Yuzbasijan-Gurkan V. Isolation and characterization of canine adipose-derived mesenchymal stem cells. Tissue Eng Part A. 2008;14:1007–15.
26. von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, Sundberg B, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30:1575–8.
27. Mancuso P, Raman S, Glynn A, Barry F, Murphy JM. Mesenchymal stem cell therapy for osteoarthritris: the critical role of the cell Secretome. Front Bioeng Biotechnol. 2011;9:79.
28. Li M, Khong DH, Chin LY, Singleton A, Parekkadan B. Therapeutic delivery of mesenchymal stromal cells is comparable to bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther. 2020;11:426.
29. Jossen V, van den Bos C, Eibl R, Eibl D. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. Angioprol Biotechnol. 2018;102:3981–94.
30. Cho YB, Park JK, Yoon SN, Song KH, Kim DS, Jung SH, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015;4:532–7.
32. Wood JA, Chung DJ, Park SA, Zwingenberger AL, Reilly CM, Ly I, et al. Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells: an in vivo imaging and migration study. J Ocul Pharmacol Ther. 2012;28:307–17.

33. Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine. Vet Clin North Am Small Anim Pract. 1990;20:583–613.

34. Park SA, Good KL, Thomasy SM, Kass PH, Murphy CJ. Effect of withdrawing chronic topical immune modulating treatment on Schirmer tear test values in dogs with dry eye disease: relevance to dry eye studies. J Ocul Pharmacol Ther. 2021;37:394–8.

35. Rhodes M, Heinrich C, Featherstone H, Braus B, Manning S, Cripps PJ, et al. Parotid duct transposition in dogs: a retrospective review of 92 eyes from 1999 to 2009. Vet Ophthalmol. 2012;15:213–22.

36. Sgrignoli MR, Silva DA, Nascimento FF, Sgrignoli DAM, Nai GA, da Silva MG, et al. Reduction in the inflammatory markers CD4, IL-1, IL-6 and TNF alpha in dogs with keratoconjunctivitis sicca treated topically with mesenchymal stem cells. Stem Cell Res. 2019;39:101525.

37. Safarini OA, Keshavamurthy C, Patel P. Calcineurin Inhibitors. [Updated 2022 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558995/.

38. van Megen KM, van’t Wout ET, Lages Motta J, Dekker B, Nikolic T, Roep BO. Activated mesenchymal stromal cells process and present antigens regulating adaptive immunity. Front Immunol. 2019;10:694.

39. DeLuca LA, Glass SG. Johnson RE, Burger M. Description and evaluation of a canine volunteer blood donor program. J Appl Anim Welf Sci. 2006;9:129–41.

40. Bahamondes F, Flores E, Cattaneo G, Bruna F, Conget P. Omental adipose tissue is a more suitable source of canine mesenchymal stem cells. BMC Vet Res. 2017;13:166.

41. Vieira NM, Brandalise V, Zucconi E, Secco M, Strauss BE, Zatz M. Isolation, characterization, and differentiation potential of canine adipose-derived stem cells. Cell Transplant. 2010;19:279–89.

42. Guercio A, Di Marco P, Casella S, Cannella V, Russotto L, Purpari G, et al. Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroradial joints. Cell Biol Int. 2012;36:189–94.

43. Russell KA, Chow NH, Dukoff D, Gibson TW, LaMarre J, Betts DH, et al. Characterization and immunomodulatory effects of canine adipose tissue- and bone marrow-derived mesenchymal stromal cells. PLoS One. 2016;11:e0167442.

44. Puisant B, Barreau C, Bourin P, Clavel C, Corne J, Bousquet C, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol. 2005;129:118–29.

45. Kim HS, Kim KH, Kim SH, Kim YS, Koo KT, Kim TI, et al. Immunomodulatory effect of canine periodontal ligament stem cells on allogenic and xenogenic peripheral blood mononuclear cells. J Periodontal Implant Sci. 2010;40:265–70.

46. Lin K-J, Loi M-X, Cheng C-F, Pao H-Y, Chang Y-C, et al. Topical administration of orbital fat-derived stem cells promotes corneal tissue regeneration. Stem Cell Res Ther. 2013;4:72.

47. Gelatt KN, Peiffer RL Jr, Erickson JL, Gum GG. Evaluation of tear formation in the dog, using a modification of the Schirmer tear test. J Am Vet Med Assoc. 1975;166:368–70.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.